|
Risk
Factors for Osteoporosis
There
are still many unknown facts about osteoporosis, but certain risk factors
now associated with it are helpful in identifying those who are most prone
to developing the disease. In addition, since osteoporosis can be caused
or exacerbated by certain diseases or drugs, appropriate steps can be
taken to decrease the risk. Everyone has some risk of developing the disease
- some more than others. Dr. Robert Heaney of Creighton University at
Omaha, Nebraska, says, "Osteoporosis is a total life-style problem." You
can't change your physical heredity, but you can change the way you live.
Age
The
longer you live, the greater your chances of developing osteoporosis.
This is essentially a disease of aging, and all the physiological aspects
of growing older contribute to its development. Sluggish, older intestines
often don't absorb enough calcium to replenish the bones, and if an adequate
amount isn't consumed to begin with, the problem is compounded. Inactive
older people often remain inside and frequently do not get enough exercise
to maintain bone strength and are not exposed to enough sunshine for the
production of Vitamin D.
As
the body ages, especially after menopause, there is a decline in the secretion
of calcitonin, which discourages bone resorption. To compound the problem,
there is an increased production of PTH (parathyroid hormone), which encourages
the tearing down of bone tissue. Some research indicates that the aging
osteoblasts simply can't manufacture enough new bone for the helpful osteocytes
to keep up. As osteocytes die, there are fewer new ones to replace them,
which has an adverse effect upon bone replacement. This form of osteoporosis
is characterized by a thinning of the bones, which happens slowly over
the years without any outward sign. In many cases a bone fracture is the
first clue that a woman has this condition. But by this time, osteoporosis
has already caused irreversible damage. Loss of the spongy trabecular
bone is paramount, and results in many crushing vertebral fractures, primarily
in women between 55 and 75 years of age.
Sex
Women
with their smaller, thinner bones are far more susceptible to osteoporosis
than men. Their peak bone mass is 30 percent less than that of men so
there is simply less bone to lose. Women begin to give up bone earlier,
and the reduction goes at a much more rapid pace than in men. The calcitonin
levels are lower in women so bone destruction is not as effectively controlled.
In the early to mid 30's, bones stop growing and start weakening as they
give up calcium to the blood. Men lose bone at a constant rate, about
0.3 percent a year for the cortical bone; a slightly higher amount of
trabecular bone is destroyed. Women lose about one percent of their trabecular
bone and one percent of the cortical bone mass yearly, and that rate accelerates
dramatically after menopause. Three to seven years following menopause,
the bone loss in women averages three percent. However, as much as eight
percent can be lost from the lumbar vertebrae, which are composed mainly
of trabecular bone. The formation of new bone can't keep up with the speed
at which it's being torn down and there is a great deterioration of bone
mass. In approximately 20 years following menopause, the bones in a female
skeleton may be reduced as much as 30 percent.
All
evidence points to the fact that over a woman's lifetime, estrogen protects
bone mass while retarding the rate of loss. The longer and greater the
exposure a woman has to estrogen, the lower her risk of osteoporosis.
From puberty to menopause estrogen levels are high, and they rise during
pregnancy or when oral contraceptives are used. When production dramatically
drops as with natural or surgical menopause, the sudden decline in estrogen
level affects the complex relationship among other hormones and bone resorption
and replacement. Pre-menopausal, amenorrheic women are also at a greater
risk for osteoporosis, because their hormone level is already low and
menopause often begins early. The longer a woman lives after menopause,
the greater the risk of osteoporosis.
Race
Petite,
fair skinned Caucasian and Asian women are at a much greater risk of developing
the disease. In general, blacks have thicker bones and average ten percent
more bone mass than others. Some researchers speculate that skin pigmentation
and the higher ultraviolet levels in the tropics stimulate the production
of Vitamin D in the skin, which influences bone tissue production. Osteoporosis
is much less prevalent among blacks worldwide, and in women of the Mediterranean
regions. Others cite osteoporosis as a disease of the privileged, which
is more likely to develop in the affluent society of Europe, Scandinavia
or North America than in the Third World. The Bantu tribe of South Africa,
whose members are hardly the best fed or healthiest people in the world,
had the lowest recorded incidence of hip fractures in a 1980 study that
also evaluated people in Sweden, the United States, Yugoslavia, and Great
Britain. No one really knows why the poor are relatively free of osteoporosis
while their better-fed sisters break their bones "right and left." Dr.
Diane Meier, Co-Director of the Osteoporosis and Metabolic Bone Disease
Program at Mt. Sinai Medical Center, has investigated this contradiction.
She conducted a study of 150 black women and 150 white women, aged 25
to 65, to determine whether whites do have an inherent predisposition
to excessive bone loss or if body composition and nutritional habits are
the key to bone mass. She says, "Blacks, at least in the Northern American
population, tend to higher obesity rates and obesity is a protection against
bone loss." Dr. Meier's theory is that extra weight stimulates formation
of bone because of the increased load placed upon the skeleton. Another
factor is the ability of fat tissue to metabolize androgens, a type of
hormone which helps protect bone mass.
Family
History
"Take
a good look at your mother and grandmother to see what's in store for
you." Women with a family history of osteoporosis are much more likely
to develop this disease. Potential bone mass is a genetically determined
factor. A tendency toward early menopause may also be inherited, bringing
additional years for the bones to go without estrogen protection.
Progress
in the study of the genetics of osteoporosis has been slow. Fractures
in individuals are uncommon, making the feasibility of detecting associations
between fractures and candidate genes quite unlikely. Bone mineral density
(BMD) is a predictor of fracture, but association studies with candidate
genes, including those for vitamin D, estrogen, and androgen receptors,
have produced inconsistent and contradictory results to date. BMD is too
crude a measure to detect variations in remodeling due to genetic differences.
Some promising research has indicated, however, that a particular polymorphism
of the androgen receptor may serve as a molecular marker of risk for osteoporosis
in men.
Health
Problems Contributing to Osteoporosis
One
out of three men, and one out of five women, who sought medical care for
osteoporosis (which was first manifested as a fracture), were discovered
to have an underlying illness that contributed to the development of the
disease. Diagnosis and treatment of the underlying ailment is essential
for appropriate care. Medical conditions that may contribute to the development
of osteoporosis include:
Hyperthyroidism
(excessive amounts of thyroid hormone): The disease may be due to an overactive
thyroid gland or may be the result of taking too high a dosage or too
lengthy a regimen of the thyroid hormone in tablet form. The longer it
continues, the more severe the bone damage. This condition escalates bone
loss and after several years, can cause osteoporosis.
Hyperparathyroidism:
Overactivity of the parathyroid gland causes so much hormone to be secreted
that it keeps a persistently high level of blood calcium. There is often
wasting of bone tissue, as well as abdominal pain, mental dysfunction,
and development of kidney stones. Sometimes called the "Hungry Bone Syndrome,"
this disorder is more common than realized, and mild forms are often discovered
in routine lab tests. Since it may not cause symptoms, the silent bone
loss in postmenopausal women can be severe. The only treatment is surgical
removal of the parathyroid glands.
Cushings
Syndrome: This is a disorder in which an overactive pituitary gland
stimulates the adrenal glands to produce too much cortisone. One of the
effects is osteoporosis. A buffalo hump' develops between the shoulder
blades due to a fat pad, and often the spine is bent forward by deformities
caused by compressed vertebrae.
Rheumatoid
Arthritis: Rheumatoid arthritis is often characterized by a bone calcium
content that is 10 percent lower than normal. However, there are thick
calcium deposits along the edges of bone and around the joints. Some believe
the decrease in bone calcium results from the decreased mobility associated
with the disease; however, a similar decrease is not seen in patients
with osteoarthritis, which can also cause significant reductions in mobility.
Cortical bone in most osteoarthritic patients is tough and hard, while
that of an osteoporotic patient is often honeycomb. Those who suffer from
rheumatoid arthritis have severe pain, decreased physical activity, and
poor appetite and nutrition. Treatment with cortisone aggravates calcium
loss and bone weakness. Anti-inflammatory medications often must be taken
with antacids, which, in turn, block calcium absorption.
Cancer:
Cancerous plasma cells produce a chemical osteoclast activating factor,
OAF, which is a powerful stimulator of the production of bone-dissolving
osteoclasts. Patients with multiple myeloma often have severe osteoporosis,
and several other types of carcinoma show a particular affinity for bones.
Chemotherapy for the treatment of breast cancer has been shown to decrease
estrogen production by the ovaries, resulting in greater than expected
bone loss in treated women.
High
Blood Pressure: A study of risk factors for bone loss and related
fractures among 3500 elderly women suggested that high blood pressure
that is not adequately controlled may increase the risk of osteoporosis.
The study, reported in Lancet, suggests that high blood pressure may be
associated with abnormal calcium metabolism and bone loss.
Depression:
In a review of published research, NIMH-funded scientists reported a strong
association between depression and osteoporosis. The literature suggests
that depression may be a significant risk factor for osteoporosis. Low
bone mineral density (BMD), a major risk factor for fracture, is more
common in depressed people than in the general population. Although its
causes are unclear, major depression is associated with hormonal abnormalities
that can lead to changes in tissue, such as bone. Research suggests that
higher cortisol levels, often found in depressed patients, may contribute
to bone loss and changes in body composition.
In
one study, evidence revealed that bone density at the lumbar spine was
15% lower in 80 men and women older than 40 with major depression compared
to 57 men and women who were not depressed. Factors such as smoking, a
history of excessive or inadequate exercise, or estrogen treatment did
not affect the study, implying that depression per se had an effect on
bone mass. The association between depression, BMD, falls, and risk of
fracture was also examined in a study of 7,414 elderly women. Depression
prevalence was 6%. Depressed women were more likely to fall (70% versus
59%) and had more vertebral (11% versus 5%) and non-vertebral (28% versus
21%) fractures compared with controls. This research underlines depression
as a risk factor for osteoporotic fractures, and its identification would
improve diagnosis and treatment. When one or more other risk factors is
present, such as low BMD, family history, previous fracture, thinness,
or smoking, a clinical evaluation for osteoporosis is recommended.
The
National Institute of Mental Health (NIMH) has launched a new study of
women ages 21 to 45 who are suffering from major depression to find out
whether low bone mass is related to depression or stress hormones, such
as cortisol. During a 12-month period, researchers will monitor bone loss
and the effects of depression and stress on physical health. The study
will determine whether women with major depression and normal BMD lose
bone mass faster than women without depression, and if the drug alendronate
(Fosamax) can maintain or increase bone mass in premenopausal women with
major depression and low bone mass.
Other
Diseases: Patients with pancreatitis, severe liver disease, and emphysema
often suffer from osteoporosis; since 1948, diabetes has also been recognized
as a risk factor. Some researchers believe there is a common genetic risk
factor for both diabetes and osteoporosis. A gastrectomy often results
in poor absorption of calcium, but supplemental Vitamin D and calcium
usually resolve the problem. Those with an untreated GI malabsorption
syndrome or pancreatitis may develop magnesium deficiency, which results
in lower blood levels of calcium and leaching of calcium from the bones.
Prescribed
Medications
Many
medications contribute to osteoporosis when they are prescribed for other
conditions. In the U.S., the population over 65 years of age takes 25
percent of all medications, some of which might have begun early in life
to deplete the bones of calcium. The following medications have an adverse
effect upon bone health.
Glucocorticoids:
Long-term glucocorticoid use is the most frequent cause of drug-induced
osteoporosis, and the third leading cause of all osteoporosis in adults.
Approximately 90% of long-term users may lose significant amounts of bone,
resulting in an increased risk for fracture. Although the mechanism of
this effect has not been finally determined, it is believed that glucocorticoids
accelerate bone loss in several ways. Decreased bone formation has been
demonstrated, with an increase in osteoblast and osteocyte apoptosis.
Glucocorticoid use has also been associated with decreased absorption
of calcium in the intestine, and lowered activity of the sex hormones.
Finally, long-term uses may also contribute to muscle atrophy and progressive
loss of muscle strength. All of these factors affect bone formation and
may thus over time increase fracture risk. Risk appears to be greatest
for fractures of trabecular bone.
Oral
forms of these steroids include: Aristocort®, Celestone®, Deltasone®,
Decadron®, Medrol®, Prednisone®, Hydrocortisone®, Cortef®
and Cortisone Acetate®.
A
marked decrease in bone mineral density is typically observed within a
few weeks of initiation of treatment in adults, but bone loss will continue
even after many years of use. Particular concerns have been raised by
the increase in both long-term and intermittent use of glucocorticoids
for the treatment of a variety of childhood inflammatory diseases. Current
research focuses on the relative effects of inhaled versus oral glucocorticoid
use, and the possible benefits of prophylaxis for prevention of fractures.
Antacids:
Those that contain aluminum interfere with calcium metabolism; these include:
ALternaGEL®, Aludrox®, Amphojel®, Basaljel®, Camalox®,
Delcid®, Di-gel®, Gaviscon®, Gelusil®, Kolantyl®,
Maalox®, Mylanta®, Riopan®, Rolaids®, Silain Gel®
and Simeco®.
The
following antacids and medications for ulcer symptoms do not contain aluminum
and are thus safer for long term use: Alka Seltzer®, Alkets®,
Bi Sodol®, Citrocarbonate®, Lo-Sal®, Mylicon®, Titralac®,
Tums®, Tagamet® and Zantac®.
Diuretics:
These medications increase calcium loss in the urine, and the thiazides
are the most commonly prescribed:Diuril®, Dyazide®, Corzide®,
Diamox®, HydroDIURIL®, Aldoril®, Aldoclor®, Hydropres®,
Aldactazide®, Apresazide®, Aldoclor®, Hydropres®, Naturetin®.
Lasix® has the same effect.
Tetracyclines:
These drugs bind to calcium and impair its absorption. The medications
should be taken two to three hours apart from calcium supplements or calcium
rich food. Individuals who take these medications often have high levels
of calcium in their urine, but long lasting harm has not been proven.
Anticonvulsants:
Dilantin, phenobarbital, Primidone® and Phensuximide® all may
interfere with Vitamin D metabolism in the liver and decrease calcium
absorption. Anyone on these medications may need calcium and Vitamin D
supplements.
Miscellaneous
Medications: Some of these drugs adversely affect bone health by encouraging
the withdrawal of calcium from the bones or by interfering with Vitamin
D production:
- antituberculars including Isoniazid®, Seromycin®, Capastat®
- anticancer agents such as Dactinomycin (Cosmegen)
- Questran® to lower cholesterol levels
- Benemid® and ColBENEMID® for gout
- Doriden® and lithium
Accutane®
mobilizes calcium and supplements should be taken with long-term use.
Long-acting
benzodiazepines and sedatives have also been implicated in the development
of osteoporosis.It would be wise for any patient to consult the prescribing
physician as to the effect of his or her medications upon calcium nutrition,
because many helpful and frequently prescribed medications can have harmful
side effects on bone health.
Life
Style Factors In
addition to the risk factors listed above, there are a variety of lifestyle
characteristics that have also been shown to increase the risk for development
of osteoporosis and subsequent bone fracture. These include nutritional
status, smoking and excessive alcohol use, and exercise and general activity
level. Because modification of these factors is one of the most important
strategies for osteoporosis treatment and prevention, they will be covered
in depth in those sections of this course. |